Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
SURMOUNT-3 and SURMOUNT-4 Trials (2023) In a 2023 NEJM publication , researchers reported that Retatrutide: Produced an average of 24.2% total body weight loss at 48 weeks in individuals without diabetes Patients on the highest dose lost over 58 pounds on average Outperformed all currently available GLP-1 and GIP analogs Additional findings included: Significant reduction in liver fat (up to 85%) Improved insulin sensitivity and HOMA-IR scores Reduced blood pressure, triglycerides, and inflammation markers These results are unmatched in obesity pharmacotherapy history and suggest that Retatrutide could soon set a new gold standard for metabolic treatment
In one study , 701 people with obesity first followed a low-calorie diet for eight weeks
The standard semaglutide beginning dosage is 0.25 mg once weekly for the first four weeks
Is my rate of weight loss appropriate for my health status
